A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice
Frontiers in Microbiology · 21.03.2023 · 14
DOI: 10.3389/fmicb.2023.1145114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 21.03.2023. Verfasst von Dan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Toxoplasma gondii ( T. gondii ) can infect almost all warm-blooded animals and is a major threat to global public health. Currently, there is no effective drug or vaccine for T. gondii . In this study, bioinformatics analysis on B and T cell epitopes revealed that TGGT1_316290 (TG290) had superior effects compared with the surface antigen 1 (SAG1). TG290 mRNA-LNP was constructed through the Lipid Nanoparticle (LNP) technology and intramuscularly injected into the BALB/c mice, and its immunogenicity and efficacy were explored. Analysis of antibodies, cytokines (IFN-γ, IL-12, IL-4, and IL-10), lymphocytes proliferation, cytotoxic T lymphocyte activity, dendritic cell (DC) maturation, as well as CD4 + and CD8 + T lymphocytes revealed that TG290 mRNA-LNP induced humoral and cellular immune responses in vaccinated mice. Furthermore, T-Box 21 (T-bet), nuclear factor kappa B (NF-kB) p65, and interferon regulatory factor 8 (IRF8) subunit were over-expressed in the TG290 mRNA-LNP-immunized group. The survival time of mice injected with TG290 mRNA-LNP was significantly longer (18.7 ± 3 days) compared with the survival of mice of the control groups ( p < 0.0001). In addition, adoptive immunization using 300 μl serum and lymphocytes (5*10 7 ) of mice immunized with TG290 mRNA-LNP significantly prolonged the survival time of these mice. This study demonstrates that TG290 mRNA-LNP induces specific immune response against T. gondii and may be a potential toxoplasmosis vaccine candidate for this infection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China.
- Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, China.
- Key Laboratory of Bio-tech Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, D., Zhang, Y., Li, S., & Zheng, B. (2023). A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1145114
Vancouver
Li D, Zhang Y, Li S, Zheng B. A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1145114
BibTeX
@article{Li2023,
author = {Li, Dan and Zhang, Yizhuo and Li, Shiyu and Zheng, Bin},
title = {A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {14},
doi = {10.3389/fmicb.2023.1145114}
}
EUVIMED